Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mirvetuximab soravtansine

(MEER-veh-TUK-sih-mab SOH-rav-TAN-seen)
A drug used to treat adults with folate receptor alpha–positive ovarian epithelial, fallopian tube, or primary peritoneal cancer that has not gotten better after treatment with platinum chemotherapy. It is used in patients whose cancer was treated with one to three other systemic therapies. It is also being studied in the treatment of other types of cancer. Mirvetuximab soravtansine contains a monoclonal antibody that binds to a protein called folate receptor alpha, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Mirvetuximab soravtansine is a type of antibody-drug conjugate. Also called Elahere.
More Information
Search NCI's Dictionary of Cancer Terms